Reference SummaryWilson JW, Cancer Res 2000 Aug 15;60(16):4645-53

Title

 The effect of exogenous prostaglandin administration on tumor size and yield in Min/+ mice.

Authors

 Wilson JW; Potten CS

Journal

 Cancer Res

Volume

 60

Issue

 16

Year

 2000

Pages

 4645-53

Abstract

 This study set out to examine the effect of exogenous prostaglandin (PG) administration on tumor development in Min/+ mice. Mice were treated with the stable prostaglandin E2 analogue 16,16-dimethyl-PGE2 from 6-18 weeks of age. Mice were sacrificed, and tumor burden was assessed using morphometric techniques. Parameters measured were median tumor size, mean tumor size, the proportion of the area of the gastrointestinal mucosa covered with tumor, and the number of tumors per 1000 mm2 of gastrointestinal mucosa. In addition, proliferative and apoptotic indices were determined. These measurements were carried out for all regions of the small intestine (i.e., duodenum, jejunum, upper ileum, and lower ileum) and the large intestine (i.e., cecum and mid-colon/rectum). 16,16-Dimethyl-PGE2-treated animals showed a significant decrease in tumor burden (by approximately 50-70%), in comparison with those animals that were treated with vehicle alone (0.001% ethanol in 0.9% sterile saline), in all regions of the intestine (at P = 0.008 or better). This effect was contributed to by a reduction in the number of tumors (by approximately 20-50%) and a reduction in tumor size (by approximately 10-70%). An increase in tumor cell turnover was associated with this decrease in tumor burden, as determined by the changes in the levels of thymidine incorporation (significant at P = 0.003), apoptosis, and mitosis (nonsignificant).

Links

 J:64010 – MGI References
10969819 – National Library of Medicine/PubMed

Strain Notes

Strain Note
C57BL/6-ApcMin/+ Mice were bred in house on C57BL/6 background.

Models
Strain Model Name Treatment Agent(s) Organ Affected Frequency Model Details
C57BL/6-ApcMin/+ Intestine - Large Intestine tumor Intestine - Large Intestine

observed
C57BL/6-ApcMin/+ Intestine - Large Intestine tumor
  • 16,16-dimethyl-prostaglandin E2 (16,16dmPGE2)
 Intestine - Large Intestine

observed
C57BL/6-ApcMin/+ Intestine - Small Intestine - Duodenum tumor Intestine - Small Intestine - Duodenum

observed
C57BL/6-ApcMin/+ Intestine - Small Intestine - Duodenum tumor
  • 16,16-dimethyl-prostaglandin E2 (16,16dmPGE2)
 Intestine - Small Intestine - Duodenum

observed
C57BL/6-ApcMin/+ Intestine - Small Intestine - Ileum tumor Intestine - Small Intestine - Ileum

observed
C57BL/6-ApcMin/+ Intestine - Small Intestine - Ileum tumor
  • 16,16-dimethyl-prostaglandin E2 (16,16dmPGE2)
 Intestine - Small Intestine - Ileum

observed
C57BL/6-ApcMin/+ Intestine - Small Intestine - Jejunum tumor Intestine - Small Intestine - Jejunum

observed
C57BL/6-ApcMin/+ Intestine - Small Intestine - Jejunum tumor
  • 16,16-dimethyl-prostaglandin E2 (16,16dmPGE2)
 Intestine - Small Intestine - Jejunum

observed